Last 12 months
Inside the activity.
0 purchase rows · 15 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 13, 2016 Filed Oct 4, 2016 22:14 UTC |
BOLGER JOHN CDirector
|
GrantPredecessor Unit Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $0.05 | $0.00 |
DisclosureSEC source: 0001209191-16-144660 · doc4.xml · derivative · entry 1 BOLGER JOHN C · CIK 0001183863 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Predecessor Class D Non-Voting Common Units · 20,000 shares Expires 2026-04-12 F1 · security: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1. F2 · derivative.exercise_date: The shares or units, as applicable, subject to the option vest over a period of four years, with 1/4th of such shares or units, as applicable, vesting 12 months after April 13, 2016, and 1/16th of the remaining shares or units, as applicable, vesting at the end of every three-month period over the remaining 36 months, subject to Mr. Bolger's continued service for the Predecessor or the Issuer on each vesting date. F1 · derivative.underlying: Reflects securities of Fulgent Therapeutics LLC (the "Predecessor" or "Fulgent LLC"). Fulgent LLC is considered the predecessor of Fulgent Genetics, Inc. (the "Issuer") following completion of a reorganization transaction pursuant to which the Predecessor became a wholly owned subsidiary of the Issuer (the "Reorganization"), which was completed on September 30, 2016 in connection with the initial public offering of the Issuer and which is described in the Issuer's Registration Statement on Form S-1, as amended (File No. 333-213469). In the Reorganization, all options to purchase the Predecessor's Class D non-voting common units were cancelled in exchange for options to purchase shares of the Issuer's common stock at a ratio of 7.6-for-1. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.